Dr. Joan Fallon, Founder & CEO of Curemark, shared the story behind her title with us on Sunday, March 27, 2022.
Dr. Fallon is considered a visionary scientist who has dedicated her life’s work to championing the health and wellbeing of children worldwide. Curemark is a biopharmaceutical company focused on the development of novel therapies to treat serious diseases for which there are limited treatment options. The company’s pipeline includes a phase III clinical-stage research program for Autism, as well as programs focused on Parkinson’s Disease, schizophrenia, and addiction.
Curemark will commence the filing of a Biological Drug Application for the first novel drug for Autism under the FDA Fast Track Program. Fast Track status is a designation given only to investigational new drugs that are intended to treat serious or life-threatening conditions and that have demonstrated the potential to address unmet medical needs.
"As a child, Joan was told by her father that she could be whatever she wanted to be. That messaging along with her own innate desire to think outside the box led to her success in discovering new therapies for Autism. What struck me about Joan was her commitment to staying true to herself as a woman in science and connecting with her kindness in order to become a leader in her field."
